Insights for Oncologists on Follow-Up Data From KEYNOTE-B61 in nccRCC
January 27th 2024Martin H. Voss, MD, discusses what community oncologists should takeaway from the the extended follow-up data of the phase 2 KEYNOTE-B61 study which assessed first-line pembrolizumab plus lenvatinib for patients with non-clear cell renal carcinomas.
Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC
November 16th 2019Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />